SCHEMBL24934996

SCHEMBL24934996

CC(C)CCCC(=O)NCCCCNC(C)C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
PKM P14618 1/20 0.45
ALDH1A1 P00352 1/20 0.44
CNR1 P21554 2/20 0.43
HPGD P15428 1/20 0.43
CASP2 P42575 1/20 0.43
NAMPT P43490 1/20 0.43
TSHR P16473 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NAAA Q02083 1/20 0.41
ADRB2 P07550 2/20 0.40
ADRB1 P08588 2/20 0.40
FAAH O00519 2/20 0.39
CNR2 P34972 1/20 0.37
TP53 P04637 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
DNM1 Q05193 1/20 0.37
EPHX2 P34913 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15160714 0.96 LMNA (0.45) LMNAPKMALDH1A1CNR1HPGD
SCHEMBL19239840 0.95 NAMPT (0.45) LMNAPKMALDH1A1CNR1HPGD
SCHEMBL23320102 0.93 NAMPT (0.47) LMNAPKMALDH1A1CNR1HPGD
SCHEMBL23319056 0.93 NAMPT (0.47) LMNAPKMALDH1A1CNR1HPGD
SCHEMBL25793663 0.93 NAMPT (0.47) LMNAPKMALDH1A1CNR1HPGD
SCHEMBL23320103 0.93 NAMPT (0.47) LMNAPKMALDH1A1CNR1HPGD
SCHEMBL26818740 0.93 CASP2 (0.44) LMNAPKMALDH1A1CNR1HPGD
SCHEMBL26700781 0.93 NAMPT (0.47) LMNAPKMALDH1A1CNR1HPGD
SCHEMBL15160690 0.91 ALDH1A1 (0.50) LMNAPKMALDH1A1CNR1HPGD
SCHEMBL25063756 0.91 ALDH1A1 (0.50) LMNAPKMALDH1A1CNR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230054270-A1 BIFUNCTIONAL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) 2023-02-23 US disclosed
EP-4119546-A1 BIFUNCTIONAL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF Suzhou Kintor Pharmaceuticals, Inc. (CN) 2023-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230054270-A1 BIFUNCTIONAL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF AR, SHBG, NR5A1 LMNA 3694/4885PKM 4285/4885ALDH1A1 1653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.